Michael F. MacLean - 06 Nov 2024 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Financial Officer
Signature
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
06 Nov 2024
Net transactions value
-$4,177,915
Form type
4
Filing time
08 Nov 2024, 16:50:47 UTC
Previous filing
23 Sep 2024
Next filing
19 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Sale $1,260,017 -27,262 -22% $46.22 94,093 06 Nov 2024 Direct F1, F2
transaction RNA Common Stock Options Exercise $574,905 +65,182 +69% $8.82 159,275 06 Nov 2024 Direct F1
transaction RNA Common Stock Sale $2,954,954 -65,182 -41% $45.33 94,093 06 Nov 2024 Direct F1, F3
transaction RNA Common Stock Options Exercise $91,159 +13,875 +15% $6.57 107,968 06 Nov 2024 Direct F1
transaction RNA Common Stock Sale $629,008 -13,875 -13% $45.33 94,093 06 Nov 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -65,182 -100% $0.000000 0 06 Nov 2024 Common Stock 65,182 $8.82 Direct F1, F4
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -13,875 -19% $0.000000 60,125 06 Nov 2024 Common Stock 13,875 $6.57 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on July 8, 2024.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.86 to $48.01. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $48.01. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 All shares subject to this option have fully vested as of the date of this report.
F5 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of September 11, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the option shall be fully vested on the fourth anniversary of the Vesting Commencement Date.